Triple-negative breast cancer (TNBC; defined by ER, PR, and HER2/ERBB2-negativity) is a clinically defined subgroup of breast cancer, constituting approximately 10–15% of cancers in Western countries. This evidence concerns the gene ERBB2 and breast carcinoma.